EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

A phase I/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm

Akira Yokota, Wataru Munakata, Toru Kiguchi, Yoshiaki Ogawa, Masayuki Hino, Koji Kato, Masahiro Chiba, Daisuke Kawasaki, Kohei Wasa, Taisuke Mikasa, Kengo Takeuchi, Koji Izutsu und 2 weitere

International Journal of Hematology · 2026

DOI: 10.1007/s12185-025-04151-5 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift International Journal of Hematology, 2026. Verfasst von Akira Yokota und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Chiba Aoba Municipal Hospital, 1273-2 Aoba-cho, Chuo-ku, Chiba, Chiba, 260-0852, Japan. taroyok@xb4.so-net.ne.jp. Hauptthemen laut MEDLINE: Dendritic Cells, Recombinant Fusion Proteins, Hematologic Neoplasms, Interleukin-3. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tagraxofusp (TAG), a first-in-class CD123-targeted therapy, is a recombinant fusion protein of human interleukin-3 conjugated to a truncated diphtheria toxin payload. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive orphan hematologic cancer with a poor prognosis, and is derived from plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit alpha (IL3RA or CD123). This open-label phase I/II study evaluated the efficacy and safety of TAG in 11 Japanese BPDCN patients, of whom seven were treatment-naïve (TN) and four had relapsed/refractory (R/R) disease. In the phase I portion, seven patients (five TN, two R/R) were treated, and no dose-limiting toxicity was observed, with 12 μg/kg/day tolerated. In the phase II portion, four patients (two TN, two R/R) were treated. Among the seven TN BPDCN patients, the rate of complete response (CR) + clinical CR (CRc: CR with minimal residual skin abnormality) was 57.1% (90% confidence interval [CI], 22.5–87.1), and the lower limit of the 90% CI (22.5%) exceeded the pre-specified threshold of 10%. Common adverse events included increased alanine aminotransferase (81.8%) and aspartate aminotransferase (72.7%), hypoalbuminemia, hypokalemia, and capillary leak syndrome (54.5%). The results indicate that TAG was effective and had a manageable safety profile in Japanese BPDCN patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsRecombinant Fusion ProteinsHematologic NeoplasmsInterleukin-3HumansMaleMiddle AgedFemaleAgedAdultJapanInterleukin-3 Receptor alpha SubunitTreatment OutcomeBlastic Plasmacytoid Dendritic Cell NeoplasmEast Asian People

Stichwörter der Autor:innen

Blastic plasmacytoid dendritic cell neoplasmCD123SL-401Tagraxofusp

Substanzen

tagraxofuspRecombinant Fusion ProteinsInterleukin-3Interleukin-3 Receptor alpha Subunit

Autor:innen und Institutionen

  • Department of Hematology, Chiba Aoba Municipal Hospital, 1273-2 Aoba-cho, Chuo-ku, Chiba, Chiba, 260-0852, Japan. taroyok@xb4.so-net.ne.jp.
  • Department of Hematology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
  • Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan.
  • Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
  • Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Osaka, Japan.
  • Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.

Zitieren

APA

Yokota, A., Munakata, W., Kiguchi, T., Ogawa, Y., Hino, M., Kato, K., Chiba, M., Kawasaki, D., Wasa, K., Mikasa, T., Takeuchi, K., Izutsu, K., Suzuki, R., & Study Group (2026). A phase I/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm. International Journal of Hematology. https://doi.org/10.1007/s12185-025-04151-5

Vancouver

Yokota A, Munakata W, Kiguchi T, Ogawa Y, Hino M, Kato K, et al. A phase I/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm. International Journal of Hematology. 2026. doi:10.1007/s12185-025-04151-5

BibTeX
@article{Yokota2026,
  author = {Yokota, Akira and Munakata, Wataru and Kiguchi, Toru and Ogawa, Yoshiaki and Hino, Masayuki and Kato, Koji and Chiba, Masahiro and Kawasaki, Daisuke and Wasa, Kohei and Mikasa, Taisuke and Takeuchi, Kengo and Izutsu, Koji and Suzuki, Ritsuro and Study Group, Study Group},
  title = {A phase I/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm},
  journal = {International Journal of Hematology},
  year = {2026},
  doi = {10.1007/s12185-025-04151-5}
}
Kostenlos starten →